In this issue of MIMS Gastroenterology Supplement, we bring you clinical updates related to hepatitis B, and also a symposium highlight in conjunction with the launch of tenofovir disoproxil fumarate (Ricovir®; Mylan Laboratories) in Malaysia.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
A mixture of the flavonoids diosmin, troxerutin, and hesperidin is safe and effective for the symptomatic management of patients with acute haemorrhoidal disease, a prospective, randomised, triple-blind, controlled trial revealed.